The Food and Drug Administration (FDA) has extended the review period for the supplemental New Drug Application (sNDA) for tapinarof cream, 1% in the treatment of atopic dermatitis in adults and ...

Organon, which is seeking approval of Vtama as a treatment for atopic dermatitis, said the FDA set a new target action date of March 12 for a decision after requesting the final datasets and ...

Organon , a global healthcare company with a mission to improve the health of women throughout their lives, today announced that the U.S. Food and Drug Administration (FDA) extended by three months ...

DelveInsight's 'Exosomes Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and ...

An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug ...

Organon (NYSE:OGN) is scheduled to announce Q3 earnings results on Thursday, October 31st, before market open. JP Morgan does not expect any major surprise in the Q3 earnings, with the generic version ...

Jersey City-based Organon has completed its acquisition of Dermavant Sciences Ltd. from Roivant. Dermavant is a company ...

Organon has completed the acquisition of Dermavant Sciences, a subsidiary of Roivant, expanding its dermatology portfolio.

The European Commission (EC) has approved AstraZeneca ‘s Fasenra (benralizumab) as an add-on therapy for adults with ...

Roivant Sciences ( (ROIV) ) has shared an update. Organon has successfully acquired Dermavant Sciences, expanding its dermatology portfolio ...

Coastal Financial Corporation (Nasdaq: CCB) (the "Company”, "Coastal", "we", "our", or "us"), the holding company for Coastal ...

Organon expands dermatology capabilities through completion of Dermavant acquisition, including nonbiologic, non-steroidal VTAMA Cream, 1% ...